Federal Agency · National Institutes of Health
Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
Last updated: September 9, 2026
Posted November 18, 2024
Funding
Funding amount not specified
Closes
September 7, 2026
NAICS
541714
Similar grants still open
- Delta Community, Environment, and Climate Grant ProgramSacramento-San Joaquin Delta Conservancy · closes October 23, 2026
- Assisting Specialty Crop Exports: Low Oxygen Storage and Packaging Systems for U.S. Tree Nuts with Phytosanitary TraceabilityForeign Agricultural Service · closes October 26, 2026
- RESTORE Act Direct Component – Construction and Real Property Acquisition ActivitiesU.S. Dept. of Treasury RESTORE Act Program · closes October 31, 2026
- Middendorf Foundation Inc — Baltimore City/County Arts, Culture, Education, Environment, Healthcare, Historic Preservation, Social Services GrantsMiddendorf Foundation Inc · closes November 1, 2026
- NOVA-Education Education and Enforcement-Nonhighway and Off-Road Vehicle Activities ProgramWashington Recreation and Conservation Office · closes November 3, 2026
- RTP Recreational Trails ProgramWashington Recreation and Conservation Office · closes November 3, 2026
- NOVA-Trails Trails-Nonhighway and Off-Road Vehicle Activities ProgramWashington Recreation and Conservation Office · closes November 3, 2026
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)National Institutes of Health · closes November 6, 2026
This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present NOFO (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data. Applicants proposing to develop lines of inquiry where feasibility or proof of concept has been established should apply to the companion R01 NOFO (PAR-xx-xxx).
Eligibility
- Funded by NIH
- Programs related to bridge
Award details
Applications close on September 7, 2026.
Categories
Environment Energy
This grant is no longer accepting applications. Get matched to open grants like it, or browse the ones above.
See similar open grants ↑Applications closed — listing kept for reference.·Source: Grants.gov·Last seen Sep 7, 2026
